Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Freya Biosciences | 2024 | Series A | $11.8M | Boston |
| Elicit Plant | 2024 | Series B | $48.0M | Vilhonneur |
| Purespring Therapeutics | 2024 | Series B | $104.5M | London |
| Micropep Technologies | 2024 | Series B | $11.0M | Ramonville-saint-agne |
| Arzeda | 2024 | Series C | $38.0M | Seattle |
| NOVAMEAT | 2024 | Series A | $19.3M | Barcelona |
| deepc | 2024 | Series A | $13.0M | Munich |
| Myricx Bio | 2024 | Series A | $115.3M | London |
| May Health | 2024 | Series B | $24.8M | Paris |
| Cure51 | 2024 | Seed | $16.3M | Paris |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 26 | Freya Biosciences | Series A | $11.8M | Boston, United States |
| 27 | Elicit Plant | Series B | $48.0M | Vilhonneur, France |
| 28 | Purespring Therapeutics | Series B | $104.5M | London, United Kingdom |
| 29 | Micropep Technologies | Series B | $11.0M | Ramonville-saint-agne, France |
| 30 | Arzeda | Series C | $38.0M | Seattle, United States |
| 31 | NOVAMEAT | Series A | $19.3M | Barcelona, Spain |
| 32 | deepc | Series A | $13.0M | Munich, Germany |
| 33 | Myricx Bio | Series A | $115.3M | London, United Kingdom |
| 34 | May Health | Series B | $24.8M | Paris, France |
| 35 | Cure51 | Seed | $16.3M | Paris, France |
Freya Biosciences is a clinical-stage women's health company pioneering a new class of microbial immunotherapies.
Elicit Plant is an agro-biotech company thatfocuses on enhancing the resilience of crops under drought conditions through natural processes.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
Micropep Technologies is a biotech company that focused on biological alternatives to agrochemicals.
Arzeda is a protein design company that creates and manufactures proteins and enzymes for pharmaceuticals and industrial chemicals.
NOVAMEAT develops cutting-edge technological solutions to feed the planet's growing population with plant-based foods.
The AI Operating System for the Future of Radiology
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
May Health develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility.
Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features.
BetterOmics is a SaaS platform that empowers professionals in the life sciences industry with cutting-edge AI and computational techniques.
Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.
Capturing the human-bacterial relationship to address the seemingly impossible question - will this drug work [for me?]
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
DMC Biotechnologies produces bio-based chemicals using fermentation.
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Meiogenix is a biotechnology company that develops breeding technologies.
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.
Home Biosciences is a European venture builder dedicated to biotech.
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.
Sofinnova Partners has invested in 116 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Sofinnova Partners's top investment sectors include Biotechnology, Therapeutics, Life Science, Medical, Health Care. The firm invests across 30 different industry categories.
Among tracked funding rounds, AAVantgarde Bio received $141.0M in a Series B round. Sofinnova Partners's total known invested capital is $4.1B.
Sofinnova Partners's average investment size is $53.1M across its portfolio of 116 companies.
Recent Sofinnova Partners portfolio additions include Freya Biosciences, Elicit Plant, Purespring Therapeutics, Micropep Technologies, Arzeda. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors